Biochemical and molecular markers in renal cell carcinoma: an update and future prospects

Abstract Cancer is a big problem in the developed world as well as in developing countries. Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancies and 90–95% of neoplasms arising from the kidney. RCC is more common in men than in women (2:1), and it most often occurs in patients between the ages of 50–70 years. In all cancers the cancerous cells release particular kind of proteins (called tumour markers) and blood tests are used to detect the presence of these markers. These tumour markers nowadays are an area of interest for oncologists who search for a possible solution in the detection and treatment of RCC. Different kinds of biochemical and molecular markers such as ferritin, MN/CA9, apoptotic index, p53, IL-2, gamma-enolase, CD44, CD95, chromosome instability and loss of heterozygosity have been tested in RCC, but so far no marker fulfils one or the other criteria to be considered as an ideal marker for RCC. This review gives basic and updated information about the different kinds of biomarkers studied in RCC and about the role implementation of genomics and proteomics in RCC.

[1]  G. Landberg,et al.  Cyclin E and p27 protein content in human renal cell carcinoma: Clinical outcome and associations with cyclin D , 2002, International journal of cancer.

[2]  I. Charles,et al.  Nitric oxide induces coupling of mitochondrial signalling with the endoplasmic reticulum stress response , 2004, Nature Cell Biology.

[3]  J. G. Park,et al.  PTEN gene mutations in colorectal cancers displaying microsatellite instability. , 2001, Cancer letters.

[4]  N. Ordóñez.  The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. , 2004, Human pathology.

[5]  N. Anderson,et al.  Analysis of changes in acute‐phase plasma proteins in an acute inflammatory response and in rheumatoid arthritis using two‐dimensional gel electrophoresis , 1998, Electrophoresis.

[6]  Kanda,et al.  MN/CA9 gene expression as a potential biomarker in renal cell carcinoma , 1999, BJU international.

[7]  W. Oyen,et al.  Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  X. Zhang,et al.  Cell proliferation and apoptosis with BCL-2 expression in renal cell carcinoma. , 2000, Urology.

[9]  A. Imam,et al.  Monoclonal antibody to a proximal nephrogenic renal antigen: immunohistochemical analysis of formalin-fixed, paraffin-embedded human renal cell carcinomas. , 1989, Cancer research.

[10]  R. Walther,et al.  Human agmatinase is diminished in the clear cell type of renal cell carcinoma , 2004, International journal of cancer.

[11]  H. E. Solberg,et al.  Rising erythrocyte sedimentation rate during several years before diagnosis can be a predictive factor in 70% of renal cell carcinoma patients. The benefit of knowing subject‐based reference values , 1996, Journal of internal medicine.

[12]  D. Carvajal,et al.  Down‐regulation of the pharmacokinetic‐pharmacodynamic response to interleukin‐12 during long‐term administration to patients with renal cell carcinoma and evaluation of the mechanism of this “adaptive response” in mice , 1999, Clinical pharmacology and therapeutics.

[13]  Y. Ben-Ari,et al.  A cautionary note on the use of the TUNEL stain to determine apoptosis , 1995, Neuroreport.

[14]  M. Kralj,et al.  p21WAF1/CIP1 is more effective than p53 in growth suppression of mouse renal carcinoma cell line Renca in vitro and in vivo , 2003, Journal of Cancer Research and Clinical Oncology.

[15]  R. Henriksson,et al.  LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT–PCR and immunohistochemical analysis , 2003, British Journal of Cancer.

[16]  M. Dimopoulos,et al.  Prognostic significance of CA 125, CD44, and epithelial membrane antigen in renal cell carcinoma. , 2003, Urology.

[17]  R. Dahiya,et al.  DNA mismatch repair genes in renal cell carcinoma. , 2003, The Journal of urology.

[18]  K Koiso,et al.  Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. , 1997, European urology.

[19]  A. Valencia,et al.  A gene network for navigating the literature , 2004, Nature Genetics.

[20]  R. Brown,et al.  BCL-2 Family Proteins , 2019, Methods in Molecular Biology.

[21]  M. Gore,et al.  Plasma neopterin as an adjunct to C-reactive protein in assessment of infection. , 1991, Clinical chemistry.

[22]  G. Curt,et al.  Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512). , 1988, Cancer research.

[23]  J. Kuszak,et al.  Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. , 1991, Cancer research.

[24]  B. Kraupp,et al.  In situ detection of fragmented dna (tunel assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: A cautionary note , 1995, Hepatology.

[25]  P. Carroll,et al.  Frequently deleted loci on chromosome 9 may harbor several tumor suppressor genes in human renal cell carcinoma. , 2001, The Journal of urology.

[26]  D. Sidransky,et al.  Role of the p16 tumor suppressor gene in cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Viviane,et al.  Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. , 1996, The American journal of pathology.

[28]  I. Fidler,et al.  Activation of nitric oxide synthase gene for inhibition of cancer metastasis , 1996, Journal of leukocyte biology.

[29]  C. Kablitz,et al.  Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. , 1992, The Journal of clinical investigation.

[30]  P. Krammer,et al.  Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[31]  M. Yamakawa,et al.  Expression of cell cycle markers in colorectal carcinoma: Superiority of cyclin A as an indicator of poor prognosis , 1999, International journal of cancer.

[32]  P. McCue,et al.  Genetic markers in renal cell carcinomas. , 2001, Human pathology.

[33]  A. Nagy,et al.  Frequent allelic changes at chromosome 7q34 but lack of mutation of the BRAF in papillary renal cell tumors , 2003, International journal of cancer.

[34]  A. Novick,et al.  Differential protein profiling in renal‐cell carcinoma , 2004, Molecular carcinogenesis.

[35]  Damian Smedley,et al.  Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma , 1997, Oncogene.

[36]  A. Görg,et al.  The current state of two‐dimensional electrophoresis with immobilized pH gradients , 2000, Electrophoresis.

[37]  IF You Discover,et al.  THE BIOLOGICAL SCIENCE. , 1923, Science.

[38]  R. N. Macsween,et al.  Expression of tissue polypeptide antigen (TPA) in fetal and adult liver: changes in liver disease. , 1987, Journal of clinical pathology.

[39]  H. Takada,et al.  Neuron-specific enolase in hemophagocytic lymphohistiocytosis: a potential indicator for macrophage activation? , 2000, International journal of hematology.

[40]  Zhong-Hui Duan,et al.  Microarray gene expression profiling and analysis in renal cell carcinoma , 2004, BMC urology.

[41]  Z. Kırkalı,et al.  Serum Ferritin as a Clinical Markerfor Renal Cell Carcinoma: Influenc e of Tumor Size and Volume , 1999, Urologia Internationalis.

[42]  R. Yen,et al.  Tissue polypeptide specific antigen (TPS) as a tumor marker in renal cell carcinoma. , 2002, Anticancer research.

[43]  John C Reed,et al.  Bcl-2 family proteins , 1998, Oncogene.

[44]  M. Rüdiger.  Vinculin and alpha-catenin: shared and unique functions in adherens junctions. , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[45]  A. Rosman,et al.  Serum Ferritin Iron, a New Test, Measures Human Body Iron Stores Unconfounded by Inflammation , 1997, Stem cells.

[46]  F. Erdoğan,et al.  Prognostic significance of morphologic parameters in renal cell carcinoma , 2004, International journal of clinical practice.

[47]  W. Zong,et al.  NF-kappaB: Key mediator of inflammation-associated cancer , 2004, Cancer biology & therapy.

[48]  F. Leach,et al.  Mismatch Repair Gene Mutations in Renal Cell Carcinoma , 2002, Cancer biology & therapy.

[49]  C. Valansi,et al.  Increased levels of a 21-kDa protein in the circulation of tumor-bearing patients. , 1994, Cancer detection and prevention.

[50]  K. Grankvist,et al.  Evaluation of five glycoprotein tumour markers (CEA, CA‐50, CA‐19‐9, CA‐125, CA‐15‐3) for the prognosis of renal‐cell carcinoma , 1997, International journal of cancer.

[51]  P. Bassi,et al.  Prognostic factors in renal cell carcinoma. , 1988, European urology.

[52]  F. Marshall,et al.  Cadherin-6, a cell adhesion molecule specifically expressed in the proximal renal tubule and renal cell carcinoma. , 1997, Cancer research.

[53]  P. Boffetta,et al.  Chromosomal Aberrations in Lymphocytes of Healthy Subjects and Risk of Cancer , 2005, Environmental health perspectives.

[54]  Kanefusa Kato,et al.  Evaluation of gamma-enolase as a tumor marker for renal cell carcinoma. , 1989, The Journal of urology.

[55]  B. Seliger,et al.  Identification of markers for the selection of patients undergoing renal cell carcinoma‐specific immunotherapy , 2003, Proteomics.

[56]  B. Seliger,et al.  Analysis of the MHC Class I Antigen Presentation Machinery in Human Embryonal Carcinomas: Evidence for Deficiencies in TAP, LMP and MHC Class I Expression and their Upregulation by IFN‐γ , 1997, Scandinavian journal of immunology.

[57]  P. Lissoni,et al.  Pretreatment serum markers and lymphocyte response to interleukin-2 therapy , 1999, British Journal of Cancer.

[58]  G. Batist,et al.  Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  L. Azzoni,et al.  Argyrophilic Nuclear Organizer Region Counts and Ki-67 Scores in Human Renal Cell Carcinoma , 1991 .

[60]  A. Zetterberg,et al.  Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. , 1996, European journal of biochemistry.

[61]  Min Cheol Lee,et al.  Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth , 2003, Journal of surgical oncology.

[62]  T. Maniatis,et al.  NF-κB: A lesson in family values , 1995, Cell.

[63]  B. Churchill,et al.  The results of radical nephrectomy for renal cell carcinoma. , 1968, Transactions of the American Association of Genito-Urinary Surgeons.

[64]  B. Björklund.  Tissue polypeptide antigen (TPA): Biology, biochemistry, improved assay methodology, clinical significance in cancer and other conditions, and future outlook. , 1978, Antibiotics and chemotherapy.

[65]  J. Cerhan,et al.  Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma. , 2003, The Journal of urology.

[66]  Yasuaki Yamada,et al.  Soluble Fas (APO-1/CD95) Isoform in Adult T-Cell Leukemia , 2001, Leukemia & lymphoma.

[67]  D. Sidransky,et al.  Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. , 1995, Cancer research.

[68]  G. Camussi,et al.  Expression of CD154 on renal cell carcinomas and effect on cell proliferation, motility and platelet‐activating factor synthesis , 2002, International journal of cancer.

[69]  O. Frankfurt,et al.  Identification of Apoptotic Cells by Formamide-induced DNA Denaturation in Condensed Chromatin , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[70]  N. Dawson,et al.  Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma. , 1985, The American journal of medicine.

[71]  D. Gingras,et al.  The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis. , 2002, Molecular cancer therapeutics.

[72]  M. Gilcrease,et al.  Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence , 1999, Cancer.

[73]  Suyun Huang,et al.  Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency. , 2003, Free radical biology & medicine.

[74]  M. Fukushima,et al.  Significance of thymidylate synthase activity in renal cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  A. Agarwal,et al.  NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer. , 1999, Anticancer research.

[76]  S. Yoshida,et al.  Suppression of retinal neovascularization by the NF-kappaB inhibitor pyrrolidine dithiocarbamate in mice. , 1999, Investigative ophthalmology & visual science.

[77]  G. Batist,et al.  AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. , 2001, Expert review of anticancer therapy.

[78]  M. Rüdiger.  Vinculin and α‐catenin: shared and unique functions in adherens junctions , 1998 .

[79]  A. Llombart‐Bosch,et al.  p16INK4A and p15INK4B Gene Alteration Associated with Oxidative Stress in Renal Cell Carcinomas After the Chernobyl Accident (Pilot Study) , 2002, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[80]  Tom Maniatis,et al.  The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB , 1994, Cell.

[81]  K. Orita,et al.  Plasma neopterin/C-reactive protein ratio as an adjunct to the assessment of infection and cancer cachexia. , 1995, Immunological investigations.

[82]  E. Engleman.  Dendritic cell-based cancer immunotherapy. , 2003, Seminars in oncology.

[83]  B. Chung,et al.  Expression of the proto-oncogene Axl in renal cell carcinoma. , 2003, DNA and cell biology.

[84]  M. Del Vecchio,et al.  Renal Cancer Treatment: A Review of the Literature , 2003, Tumori.

[85]  A. Tong,et al.  Prospects for CD40-directed experimental therapy of human cancer , 2003, Cancer Gene Therapy.

[86]  I. Fidler,et al.  Therapy of cancer metastasis by activation of the inducible nitric oxide synthase , 1998, Cancer and Metastasis Reviews.

[87]  Kazuki Kobayashi,et al.  VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. , 2002, Journal of the National Cancer Institute.

[88]  P. Modrich,et al.  Mechanisms and biological effects of mismatch repair. , 1991, Annual review of genetics.

[89]  A. Heidenreich,et al.  Pyruvate Kinase Type Tumor M2 in Urological Malignancies , 2003, Urologia Internationalis.

[90]  H. Kemona,et al.  Does renal carcinoma affect the expression of P-selectin on platelets? , 2002, Neoplasma.

[91]  C. Chresta,et al.  Further characterisation of the in situ terminal deoxynucleotidyl transferase (TdT) assay for the flow cytometric analysis of apoptosis in drug resistant and drug sensitive leukaemic cells. , 1995, Cytometry.

[92]  P. Bugert,et al.  Significance of chromosome arm 14q loss in nonpapillary renal cell carcinomas , 1997, Genes, chromosomes & cancer.

[93]  E. Stanbridge,et al.  Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. , 1997, Cancer research.

[94]  R. Henriksson,et al.  Is LRIG1 a Tumour Suppressor Gene at Chromosome 3p14.3? , 2002, Acta oncologica.

[95]  W. Koopman.  Arthritis and allied conditions;: A textbook of rheumatology , 1972 .

[96]  C. Nathan,et al.  Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. , 1994, The Journal of biological chemistry.

[97]  P. Bugert,et al.  Detailed microsatellite analysis of chromosome 3p region in non‐papillary renal cell carcinomas , 1997, International journal of cancer.

[98]  S. Fukushima,et al.  Assessment of cell cycle-related elements p53, p21WAF1/Cip1, cyclin D1 and PCNA in a mixed transitional cell carcinoma and adenocarcinoma of the renal pelvis: a case report. , 1998, Japanese journal of clinical oncology.

[99]  P. Hornsby,et al.  Presence of double-strand breaks with single-base 3' overhangs in cells undergoing apoptosis but not necrosis , 1996, The Journal of cell biology.

[100]  R. Kettmann,et al.  Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. , 1996, Genomics.

[101]  T. Hunter,et al.  Regulation of cell growth and transformation by tyrosine-specific protein kinases: the search for important cellular substrate proteins. , 1983, Current topics in microbiology and immunology.

[102]  I. Adcock,et al.  The effects of glucocorticoids on phorbol ester and cytokine stimulated transcription factor activation in human lung. , 1994, Life sciences.

[103]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[104]  J. Bell,et al.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[105]  B. Kraupp,et al.  In situ detection of fragmented dna (tunel assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: A cautionary note , 1995, Hepatology.

[106]  A. Novick,et al.  Impaired Activation of NFκB in T Cells From a Subset of Renal Cell Carcinoma Patients Is Mediated by Inhibition of Phosphorylation and Degradation of the Inhibitor, IκB , 1998 .

[107]  E. van den Berg,et al.  Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. , 2003, Human molecular genetics.

[108]  L. Medeiros,et al.  Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases , 1988, Cancer.

[109]  P. Rehak,et al.  Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. , 2004, Urology.

[110]  M. Kattan,et al.  Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors. , 2003, Urologic oncology.

[111]  J. Finke,et al.  Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. , 2003, Cancer research.

[112]  S. Fukushima,et al.  Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. , 1998, Cancer.

[113]  B. Delahunt,et al.  Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. , 2001, Human pathology.

[114]  Gail M. Williams,et al.  Apoptosis and Expression of Bcl-2, Bcl-XL, and Bax in Renal Cell Carcinomas , 2002, Cancer investigation.

[115]  H. Müller-Hermelink,et al.  Significance of conventional and new prognostic factors for locally confined renal cell carcinoma , 1995, Cancer.

[116]  R. Varshney,et al.  The development and use of microsatellite markers for genetic analysis and plant breeding with emphasis on bread wheat , 2000, Euphytica.

[117]  R. Low,et al.  Immunohistochemical analysis of BCL-2 protein expression in renal cell carcinoma. , 1999, The Journal of urology.

[118]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.

[119]  P. Lipponen.  Apoptosis in breast cancer: relationship with other pathological parameters. , 1999, Endocrine-related cancer.

[120]  G. Murphy,et al.  Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. , 1987, Anticancer research.

[121]  G. Mufti,et al.  Basic isoferritin and hypercalcaemia in renal cell carcinoma , 1982, Journal of clinical pathology.

[122]  T. Shuin,et al.  Vinculin: Its Possible Use as a Marker of Normal Collecting Ducts and Renal Neoplasms with Collecting Duct System Phenotype , 2000, Modern Pathology.

[123]  L. Chiusa,et al.  Role of the argyrophilic nucleolar organizer regions in tumor detection and prognosis. , 1995, Cancer detection and prevention.

[124]  B. Seliger,et al.  Induction of immunogenicity of a human renal‐cell carcinoma cell line by TAP1‐gene transfer , 1999, International journal of cancer.

[125]  T. Kuo,et al.  Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma , 2005, Modern Pathology.

[126]  L. Azzoni,et al.  Argyrophilic nucleolar organizer region counts and Ki-67 scores in human renal cell carcinoma. , 1991, Pathology, research and practice.

[127]  J. Robb,et al.  Apoptosis in breast carcinomas detected with monoclonal antibody to single-stranded DNA: relation to bcl-2 expression, hormone receptors, and lymph node metastases. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[128]  V. Bilim,et al.  Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients , 2004, British Journal of Cancer.

[129]  H. Kikuchi.  [Tumor markers of urinary tract carcinoma]. , 2004, Rinsho byori. The Japanese journal of clinical pathology.

[130]  E. Karapanagiotou,et al.  The clinical significance of molecular markers to bladder cancer. , 2004, Hybridoma and hybridomics.

[131]  O. Cussenot,et al.  Tumour-associated trypsin inhibitor and renal cell carcinoma. , 1995, European urology.

[132]  Kanefusa Kato,et al.  Use of Serum Gamma‐enolase and Aldolase A in Combination as Markers for Renal Cell Carcinoma , 1993, Japanese journal of cancer research : Gann.

[133]  C. Westenfelder,et al.  Erythropoietin stimulates proliferation of human renal carcinoma cells. , 2000, Kidney international.

[134]  V. Bilim,et al.  Inducible nitric oxide, synthase in renal cell carcinoma: expression in tumor thrombi and induction under hypoxic conditions. , 2003, Anticancer research.

[135]  A. Baldwin,et al.  Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation , 1993, Molecular and cellular biology.

[136]  D. Seripa,et al.  Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine , 2001, International journal of cancer.

[137]  I. Zanna,et al.  Loss of heterozygosity and methylation of p16 in renal cell carcinoma , 2003, Urological Research.

[138]  Mark Woodward,et al.  Population Distributions of C-reactive Protein in Apparently Healthy Men and Women in the United States : Implication for Clinical Interpretation , 2022 .

[139]  P. Jeannesson,et al.  Improvement in the staining and in the visualization of the argyrophilic proteins of the nucleolar organizer region at the optical level , 2005, The Histochemical Journal.

[140]  B. Seliger,et al.  Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. , 2003, Biochimica et biophysica acta.

[141]  K. Zatloukal,et al.  Expression of CD44 isoforms in human renal cell carcinomas , 1996, Virchows Archiv.

[142]  Bruce A Luxon,et al.  Genomic profiling identifies alterations in TGFβ signaling through loss of TGFβ receptor expression in human renal cell carcinogenesis and progression , 2003, Oncogene.

[143]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[144]  B. Koçak,et al.  Value of urinary NMP-22 in patients with renal cell carcinoma. , 2002, Urology.

[145]  A Krishan,et al.  Enzyme-linked immunosorbent assay (ELISA) for the specific detection of apoptotic cells and its application to rapid drug screening. , 2001, Journal of immunological methods.

[146]  K. Grankvist,et al.  Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. , 1997, European journal of cancer.

[147]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[148]  J. Atzpodien,et al.  Primary apoptosis as a prognostic index for the classification of metastatic renal cell carcinoma. , 2002, The Journal of urology.

[149]  H. Moch,et al.  Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. , 1998, The American journal of pathology.